What Makes Cooper Companies (COO) an Investment Choice?

Core Insights - The London Company Mid Cap Strategy reported a 3.2% portfolio return in Q4 2025, outperforming the Russell Midcap Index which increased by only 0.2% [1] - The US equities market saw a 2.4% rise in the Russell 3000 Index, marking the third consecutive quarter of higher returns, driven by a balance of optimism in earnings growth and concerns over AI returns and macroeconomic factors [1] Company Overview: The Cooper Companies, Inc. - The Cooper Companies, Inc. operates in the medical device sector through two segments: CooperVision (contact lenses, contributing over 65% of revenue) and CooperSurgical (women's healthcare products) [3] - The stock of The Cooper Companies, Inc. had a one-month return of 3.83% but experienced an 8.17% decline over the past 52 weeks, closing at $83.56 per share with a market capitalization of $16.612 billion on February 24, 2026 [2] Performance and Market Position - CooperVision is noted for its strong market share in an oligopolistic industry where four players control 95% of the market, benefiting from a diverse product portfolio and high customer switching costs [3] - Despite its strengths, The Cooper Companies' margins are lower than peers due to a multi-year investment cycle and industry headwinds, although there is significant potential for margin expansion as capital spending moderates [3] Investment Considerations - Recent share price weakness is attributed to cyclical pressures and execution missteps rather than fundamental deterioration, with activist involvement seen as a catalyst for operational improvements and potential business separation [3] - The valuation of The Cooper Companies is considered attractive, with recent insider buying indicating confidence in the company's future prospects [3]